Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women: Influence of various progestogens and duration of therapy

Archives of Internal Medicine

Volumn 156, Issue 15, 1996, Pages 1693-1700

  Kim, Chee Jeong ^a   Min, Young Ki ^b   Ryu, Wang Seong ^a   Kwak, Ju Won ^c   Ryoo, Un Ho ^a  

^a Chung Ang University   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CONJUGATED ESTROGEN; ESTRADIOL VALERATE; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; NORGESTREL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HORMONE SUBSTITUTION; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL;

ADULT; AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; EQUILIN; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; LIPIDS; LIPOPROTEIN(A); MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; NORGESTREL; POSTMENOPAUSE; TRIGLYCERIDES;

EID: 2442483763     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.15.1693     Document Type: Article

References (42)

1. Berg K, Dahlen G, Frick MH. Lp(a) lipoptotein and pre-beta1 -lipoprotein in patients with coronary heart disease. Clin Genet. 1974;6:230-235.
2. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986;74:758-765.
3. Genest J Jr, McNamara JR, Ordovas JM, et al. Lipoprotein cholesterol, apolipoprotein A-l and B and lipoprotein(a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol. 1992;19:792-802.
4. Hoefler G, Harnoncourt F, Paschke E, Mitrl W, Pfeiffer KH, Kostner GM. Lipoprotein(a): a risk factor for myocardial infarction. Arteriosclerosis. 1988;8: 398-401.
5. Rosengren A, Wilhelmsen L, Erikssen E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: a prospective study in a general population sample of middle aged men. BMJ. 1990;301:1248-1251.
6. Murai A, Miyahara T, Fujimoto N, Matzuda M, Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis. 1986;59:199-204.
7. Zenker G, Koeltringer P, Bone G, Niederkorn G, Pfeifler K, Juergens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke. 1986;17: 942-945.
8. Utermann G. The mysteries of lipoprotein(a). Science. 1989;246:904-910.
9. Berg K, Leren TP. Unchanged serum lipoprotein(a) concentrations with lovastatin. Lancet. 1989;2:812.
10. Vessby B, Kostner G, Lithell H, Thomis J. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein(a). Atherosclerosis. 1982;44:61-71.
11. Alber JJ, Canaba VG, Warnick GR, Hazzard WR. Lp(a) lipoprotein: relation to sinking pre-β lipoprotein, hyperlipoproteinemia and apolipoprotein B. Metabolism. 1975;24:1047-1054.
12. Maeda S, Okuno M, Abe A, Noma A. Lack of effect of probucol on serum lipoprotein(a) levels. Atherosclerosis. 1989;79:267-269.
13. Gurakar A, Hoeg JM, Kostner G, Papadopoulos NM, Brewer HB Jr. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis. 1985;57:293-301,
14. Lepre F, Campbell B, Crane S, Hickman P. Low-dose sustained release nicotinic acid(tri-BS) and lipoprotein(a). Am J Cardiol. 1992;70:133.
15. Brewer HB Jr. Effectiveness of diet and drugs in the treatment patients with elevated Lp(a) levels. In: Scanu AM, ed. Lipoprotein(a). Orlando, Fla: Academic Press lnc; 1990:211-220.
16. Nabulsi AA, Folsom AR, White A, et al, for the Atherosclerosis Risk in Communities Study Investigators. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 1993;328:1069-1075.
17. Soma M, Fumagalli R, Paoletti R, et al. Plasma Lp(a) concentration after oestrogen and progestagen in postmenopausal women. Lancet. 1991;1:612.
18. Parish E, Rolton HA, Barnes JF, Hart DM. Lipoprotein(a) concentrations in postmenopausal women taking norethisterone. BMJ. 1991;303:694.
19. Kim CJ, Jang HC, Cho DH, Min YK. Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arterioscler Thromb. 1994;14:275-281.
20. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease. Ann Intern Med. 1976;85:447-452.
21. Knopp RH. The effect of postmenopausal estrogen therapy on the incidence of arteriosclerotic vascular disease. Obstet Gynecol, 1988;72:23S-30S.
22. Lobo RA. Effects of hormone replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab. 1991;73:925-930.
23. Walsh BW, Schiff l, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement therapy on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325:1196-1204.
24. Williams KJ, Adams MR, Klopfenstein SH. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation. 1990;81:1680-1687.
25. Negre-Salvayre A, Pieraggi M, Mabile M, Salvayre R. Protective effect of 17 β-estradiol against the cytotoxicity of minimally oxidized LDL to cultured bovine aortic endothelial cells. Atherosclerosis. 1993;99:207-217.
26. Gambrell RD Jr. The menopause: benefits and risks of estrogen-progestogen replacement therapy, fertil Steril. 1982;37:457-474.
27. Smith DC, Prentice R, Thompson DJ, Herrman WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Wed. 1975:293:1164-1167.
28. Parish E, Fletcher CD, Hart DM, Dagen MM, Parkin DE. Lipoprotein and apoprotein levels in postmenopausal women during treatment with norethisterone. Clin Chim Acta. 1986;159:147-151.
29. Wahl P, Waiden CW, Knopp R, et al. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N Engl J Med. 1983;308:862-867.
30. Hirvonen E, Maelkoenen M, Manninen V. Effect of different progestogen on lipoproteins during postmenopausal replacement therapy. N Engl J Med. 1981 ; 304:560-563.
31. Naito HK. Reliability of lipid, lipoprotein, and apolipoprotein measurements. Clin Chem. 1988;34:B84-B94.
32. Moliterno DJ, Leffert CC, Lange RA, et al. Plasma lipoprotein(a) is not a risk factor for coronary atheroscĺerosis in blacks. Circulation. 1992;86(suppl l): 1-337. Abstract.
33. Vaelimaeki M, Laitinen K, Ylikahrit R, et al. The effect of moderate alcohol intake on apolipoprotein A-l-containing lipoproteins and lipoprotein(a). Metabolism. 1991;40:1168-1172.
34. Noma A, Maeda S, Okuno M, Abe A, Muto Y. Reduction of serum lipoprotein(a) levels in hyperlipidemic patients with α-tocopheryl nicotinate. Atherosclerosis. 1990;84:213-217.
35. Schimidt EB, Klausen IC, Kristensen SD, Lervanp HH, Faergeman O, Dyerberg J. The effect of Ω-3 polyunsaturated fatty acids on Lp(a). Clin Chim Acta. 1991; 198:271-277.
36. Gavish D, Brewer JL. Lipoprotein reduction by N-acetylcysteine. Lancet. 1991; 337:203-204.
37. Meilahn EN, Kuller LH, Matthews KA, Stein EA. Lp(a) concentrations among pre- and postmenopausal women over time: the Healthy Women Study. Circulation. 1991;84(suppl ll):ll-546. Abstract.
38. Kim CJ, Yim CH, Bang SK, Park CT. Apolipoprotein(a) concentrations are increased after cessation of female sex hormone production and decreased with estrogen replacement therapy. Circulation. 1993;88(suppl l):l-364. Abstract.
39. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoproteln(a) as an acute phase protein. Atherosclerosis. 1989:78: 145-150.
40. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995; 273:199-208.
41. Bush TL, Fried LP, Barrett-Conner E. Cholesterol, lipoproteins, and coronary heart disease in women. Clin Chem. 1988;34:B60-B70.
42. Kim CJ, Min YK. Apolipoprotein(a)-lowering effect of hormone replacement therapy in postmenopausal women may be one mechanism of cardioprotective effect of estrogen. J Am Coll Cardiol. 1994;23(suppl):431A. Abstract.